Focus on Biotech & AI Stocks: (Nasdaq: $IMTX) (Nasdaq: $MDAI) (NASDAQ: $BFRG) (CSE: $INVR.CN)

 Focus on Biotech & AI Stocks: (Nasdaq: $IMTX) (Nasdaq: $MDAI) (NASDAQ: $BFRG) (CSE: $INVR.CN)

 

Stocks to Watch in Tech & Cybersecurity - (Nasdaq: $KSPI) (Nasdaq: $CCTG) (Nasdaq: $HUBC) (Nasdaq: $GEN)

 

 

 

 

February 21, 2024 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Biotech, AI, Tech and Cybersecurity sectors.

 

Read this in full at https://www.investorideas.com/news/2024/main/02211Stocks.asp

 

The newest biotech companies work with T-cell therapies for cancer treatment and use AI (artificial intelligence) for medical diagnosis and treatments.

 

The latest tech companies are involved in AI (artificial intelligence) fintech and interconnect products.

 

The newest cybersecurity companies are both Nasdaq-listed and provide services around the world.

 

New Stocks Added to the Biotech/Life Sciences Directories:

Immatics N.V. (Nasdaq:IMTX) combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

 

Spectral AI, Inc. (Nasdaq: MDAI) is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs.

 

BullFrog AI Holdings, Inc. (NASDAQ:BFRG) is a technology-enabled drug development company using Artificial Intelligence and machine learning to enable the successful development of pharmaceuticals and biologics. Through its collaborations with leading research institutions, BullFrog AI is at the forefront of AI-driven drug development using its proprietary bfLEAP™ artificial intelligence platform to create and analyze networks of biological, clinical, and real-world data spanning from early discovery to late-stage clinical trials. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics.

 

New Stocks Added to the Tech Directories:

Inverite Insights Inc. (CSE:INVR) is a Vancouver-based, AI-driven software provider specializing in real-time financial data. With a vast database of over seven billion financial data points from more than four million unique Canadian consumers transactions, Inverite empowers businesses to transact more effectively with consumers through innovative software-as-a-service (SaaS) and risk-model-as-a-service (RMaaS) solutions.

 

Joint Stock Co Kaspi.kz (Nasdaq:KSPI) operates a two-sided Super App business model: the Kaspi.kz Super App for consumers and the Kaspi Pay Super App for merchants and entrepreneurs. Kaspi.kz's offerings include payments, marketplace and fintech solutions for both consumers and merchants.

 

CCSC Technology International Holdings Ltd (Nasdaq:CCTG) is a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products. The Company specializes in customized interconnect products, including connectors, cables and wire harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. The Company produces both OEM (“original equipment manufacturer”) and ODM (“original design manufacture”) interconnect products for manufacturing companies that produce end products, as well as electronic manufacturing services (“EMS”) companies that procure and assemble products on behalf of such manufacturing companies. The Company has a diversified global customer base located in more than 25 countries throughout Asia, Europe and the Americas.

 

New Stocks Added to the Cybersecurity Directories:

HUB Cyber Security Ltd (Nasdaq: HUBC) was established in 2017 by veterans of the elite intelligence units of the Israeli Defense Forces. The Company specializes in unique cyber security solutions protecting sensitive commercial and government information. The company debuted an advanced encrypted computing solution to prevent hostile intrusions at the hardware level while introducing a novel set of data theft prevention solutions. HUB Security operates in over 30 countries and provides innovative cybersecurity computing appliances and a wide range of cybersecurity services worldwide.

 

Gen Digital Inc. (NASDAQ: GEN) is a global company dedicated to powering Digital Freedom through its trusted Cyber Safety brands, Norton, Avast, LifeLock, Avira, AVG, ReputationDefender and CCleaner. The Gen family of consumer brands is rooted in providing safety for the first digital generations. Now, Gen empowers people to live their digital lives safely, privately, and confidently today and for generations to come. Gen brings award-winning products and services in cybersecurity, online privacy and identity protection to nearly 500 million users in more than 150 countries. 

 

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

 

800 665 0411 

 

Breaking Medical Technology Stock News: Aethlon Medical (NASDAQ: $AEMD) Enters Into Materials Transfer Agreement for Santersus AG’s NucleoCapture and HemoNucleoCapture Devices

 

Breaking Medical Technology Stock News: Aethlon Medical (NASDAQ: $AEMD) Enters Into Materials Transfer Agreement for Santersus AG’s NucleoCapture and HemoNucleoCapture Devices

 

Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential Synergies With its First-in-Class Hemopurifier® Blood Filtration System

 

SAN DIEGO, CA, February 21, 2024 -- (Investorideas.com Newswire) Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it entered into a Materials Transfer Agreement (MTA) with Santersus AG, a Zurich-London based, privately held therapeutic medical device company, for Santersus’ NucleoCapture and HemoNucleoCapture devices.

 

Read this in full at: https://www.investorideas.com/news/2024/02211AEMD-NucleoCapture-HemoNucleoCapture-Devices.asp

Under the terms of the MTA, Santersus will supply Aethlon with NucleoCapture and HemoNucleoCapture devices, designed to remove Neutrophil Extracellular Traps (NETs), which are toxic to tissues and organs and are implicated in the pathophysiology of cancer, sepsis, autoimmune diseases, such as lupus, and ischemia reperfusion injury in organ transplantation.

 

Aethlon will perform initial pre-clinical studies to examine the NucleoCapture and HemoNucleoCapture devices, alone, and in combination with Aethlon’s Hemopurifier® -- a therapeutic blood filtration system designed to bind and remove harmful exosomes and life-threatening viruses from blood and other biological fluids -- to assess their ability to remove important targets in samples from cancer patients, as well as from perfusates from kidneys that have undergone machine perfusion as part of the renal transplantation process.

 

"We look forward to initiating pre-clinical studies shortly, to expand upon the data that Santersus has generated in sepsis and liver and lung transplantation, and more importantly, to explore potential synergies with our Hemopurifier, initially in oncology and renal transplantation, as well as other potential indications,” stated James Frakes, Interim Chief Executive Officer and Chief Financial Officer of Aethlon Medical. “Our belief is that the NETs removed by the NucleoCapture and HemoNucleoCapture devices, in combination with the clinical mediators removed by our Hemopurifier, could have an additive or synergistic effect in both the cancer and kidney transplant settings. The signing of the MTA represents an important milestone for both companies, as it is the first step toward a potential future collaboration.”

 

“Our collaboration with Aethlon has provided us with research and development partners with expertise and capabilities to help  advance our NucleoCapture technology platform forward in important fields, such as oncology and kidney transplantation. We are excited to continue building on the progress we've made in Santersus thus far and on taking the next steps forward in executing on our plans to advance NucleoCapture technology,” commented Scott Maguire, Chairman of Santersus.  “NETs are being increasingly recognized as an important element in cancer progression and metastasis. We believe extracorporeal removal of NETs using NucleoCapture either alone or in combination with Hemopurifier technology might create a transformational treatment option for patients receiving immune checkpoint inhibitors or CAR T cell therapies.”

 

About Santersus AG

Santersus AG is a clinical stage privately held therapeutic apheresis Anglo-Swiss company. In clinical trials, Santersus’ flagship medical device, NucleoCapture, has demonstrated the removal from patient blood of Neutrophil Extracellular Traps (NETs). NETs are fibers of decondensed DNA decorated with cytotoxic proteins that have been released from activated neutrophils. NETs have been recognized as one of the major driving factors in the development of sepsis, cancer, acute organ failure, autoimmune flares, and neurodegeneration, including Alzheimer’s disease. NucleoCapture has been granted designation as a Breakthrough Device by the US Food & Drug Administration (FDA). NucleoCapture blood purification technology is based on biocompatible, highly porous polymer beads conjugated with proprietary human recombinant histone H1.3 protein. Histone H1.3 protein was created in nature to act as the ultimate human DNA binding and compacting protein with single digit nanomolar DNA binding constants. As a result, in clinical trials Santersus has demonstrated that a single pass of NETs contaminated blood through the NucleoCapture device results in over 95% removal of NETs. Santersus has developed NucleoCapture for the treatment of sepsis, primary graft dysfunction after lung transplantation, reconditioning of extended criteria donor organs for liver and lung transplantation and Alzheimer’s disease.

 

Additional information can be found at www.Santersus.com

 

About Aethlon and the Hemopurifier®

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

 

Additional information can be found at www.AethlonMedical.com.

 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to successfully raise additional capital and to complete development of the Hemopurifier and to successfully demonstrate the utility of the Hemopurifier in cancer and infectious diseases; the Company’s ability to demonstrate synergies of the Hemopurifier with the NucleoCapture and HemoNucleoCapture devices; the Company’s ability to enter into a future collaboration with Santersus; the Company’s ability to complete the internal binding study of relevant extracellular vesicles; the Company’s ability to commence and manage its clinical trials; and other potential risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2023, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

 

Company Contact:
Jim Frakes
Interim Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.

Jfrakes@aethlonmedical.com  

 

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com  

917-513-5303

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

 

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

 

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: Aethlon Medical, Inc. (NASDAQ:AEMD) is a paid featured stock on Investorideas.com More disclaimer info:  https://www.investorideas.com/About/News/Clientspecifics.asp  https://www.investorideas.com/About/Disclaimer.asp

Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

 

Focus on Biotech Stocks: (NASDAQ: $CRDL) (NASDAQ: $KA) (TSXV: $MDCX.V) (OTCQB: $SKYE)

 Focus on Biotech Stocks: (NASDAQ: $CRDL) (NASDAQ: $KA) (TSXV: $MDCX.V) (OTCQB: $SKYE)

 

Life Sciences Stocks to Watch: (NASDAQ: $ACHV) (NASDAQ: $NRBO) (Nasdaq: $BTSG) (NASDAQ: $AIMD)

 

 

 

 

February 16, 2024 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Biotech sector.

 

Read this in full at: https://www.investorideas.com/news/2024/main/02161Stocks.asp

 

The newest biotech companies are involved in treatment of heart disease, cancer, eye disease, nicotine addiction, women’s health and home health care.

 

New Stocks Added to the Biotech/Life Sciences Directories:

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.

 

Kineta, Inc. (NASDAQ: KA) is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy. The company’s immuno-oncology pipeline includes KVA12123, a novel VISTA blocking immunotherapy currently in a Phase 1/2 clinical trial in patients with advanced solid tumors, and a preclinical monoclonal antibody targeting CD27.

 

Medicus Pharma Ltd. (TSXV:MDCX) is a clinical stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials. Through our diverse experience and extensive industry network, we are building Medicus into a leading pharmaceutical holding company, committed to delivering better treatment outcomes and alleviate pain and suffering. Utilizing a thesis driven collaborative process, we identify, acquire and advance relatively de-risked clinical stage assets through clinical development and commercialization. Skinject Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell and squamous cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The company currently has an FDA approved phase 2 trial actively recruiting patients.

 

Skye Bioscience, Inc. (OTCQB: SKYE) is focused on unlocking the pharmaceutical potential of the endocannabinoid system to treat diseases with metabolic, inflammatory, and fibrotic processes. Backed by leading life science venture investors, Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with significant clinical and commercial differentiation. Nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1, showed a favorable safety and tolerability profile in a Phase 1 study. Skye plans to start a Phase 2 clinical trial in obesity comparing monotherapy and combination arms of nimacimab and a GLP-1R agonist in mid-2024. SBI-100 Ophthalmic Emulsion, a CB1 agonist, is currently being studied in a Phase 2 clinical trial of patients with glaucoma and ocular hypertension, with interim data expected in Q1 2024.

 

Achieve Life Sciences, Inc. (NASDAQ: ACHV) focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline. There are an estimated 28 million adults in the United States alone who smoke combustible cigarettes. Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually. More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke. In addition, there are over 11 million adults in the United States who use e-cigarettes, also known as vaping. In 2023, approximately 2.1 million middle and high school students in the United States reported using e-cigarettes. Currently, there are no FDA-approved treatments indicated specifically as an aid to nicotine e-cigarette cessation.

 

NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In preclinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists.

 

BrightSpring Health Services, Inc. (Nasdaq:BTSG) is the parent company of leading healthcare service lines that provide complementary home- and community-based pharmacy and provider health solutions for complex populations in need of specialized and/or chronic care. Through the company’s high-quality and impactful pharmacy, primary care and home health care, and rehabilitation and behavioral health services, and through its skilled and dedicated employees, we provide comprehensive care and clinical solutions in all 50 states to over 400,000 customers, clients and patients daily.

 

Ainos, Inc. (NASDAQ:AIMD) is a diversified healthcare company focused on the development of novel point-of-care testing (POCT), low-dose VELDONA® interferon therapeutics, and synthetic RNA-driven preventative medicine. The company's products include VELDONA® clinical-stage human therapeutics, VELDONA® Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. The lead POCT candidate, Ainos Flora, is intended to be a telehealth-friendly POCT for women's health and certain common STIs.

 

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

Read Investor Ideas latest Biotech stock commentary

 

Cancer Immunotherapy Stocks to Watch (NASDAQ: ONCY) (TSX: ONC) (Nasdaq: CADL) (Nasdaq: BNTX) (NASDAQ: IMTX)

February 15, 2024 Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on cancer immunotherapy featuring Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

 

800 665 0411

 

 

 

Breaking Life Sciences News: Pressure BioSciences (OTCQB: $PBIO) Completes Relocation into New Manufacturing Facility, Consolidating R&D with Expanded UltraShear Equipment Development and Contract Manufacturing; @ir_pressurebio

 

Breaking Life Sciences News: Pressure BioSciences (OTCQB: $PBIO) Completes Relocation into New Manufacturing Facility, Consolidating R&D with Expanded UltraShear Equipment Development and Contract Manufacturing; @ir_pressurebio

 

Relocation Delivers Substantially Increased Manufacturing Space, Vastly Improved Operating Efficiencies, and Measurable Cost Savings for Unencumbered Growth through Multi-Year Expansion Plans

 

CANTON, Mass., Feb. 15, 2024  -- (Investorideas.com Newswire) Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemulsion products and services for the health & wellness, food & beverage, pharmaceutical, and other industries, today celebrated a significant milestone in its accelerating growth journey. The Company announced the consolidation of its Boston area operations, uniting all of its personnel into a single, cutting-edge facility designed to accommodate expanded R&D capabilities, advanced equipment development and production, formulation services, and contract manufacturing based on its patented Ultra Shear Technology (UltraShear™ or UST™) platform. The new building is currently being transformed into a state-of-the-art manufacturing facility.

 

Read this news, featuring PBIO in full at https://www.investorideas.com/news/2024/cannabis/02151PBIO-UltraShear-Equipment-Development.asp

 

Strategically located in the Boston suburb of Canton, MA, the new facility will provide PBIO with a larger, more efficient space to continue its groundbreaking work in high pressure nanotechnology platform development – and UltraShear technology in particular. The state-of-the-art facility is to be equipped with the latest modern utilities and amenities, and will house dedicated areas for R&D, equipment production, formulation services, and product manufacturing. This move, consolidating R&D with all other departments of the Company, aims to streamline and achieve new production efficiencies, reduce costs, and foster innovation within a collaborative and dynamic work environment.

 

Ken Micciche, PBIO’s Director of Business Development, commented: “We are very excited about the opportunities this consolidation and expansion presents. The move reinforces our commitment to accelerating development and production capabilities, delivering exceptional products and services, advancing the field of high-pressure nanotechnology, fostering collaborations with academic and industry partners, and supporting our expected explosive growth in the direct-to-consumer area, led by our newly acquired subsidiary company Uncle Bud’s Health & Wellness.”

 

Key Features of the New Facility:

Product Manufacturing Suites: PBIO is committed to meeting the increasing demand for its innovative nanoemulsion products, delivering breakthrough performance in fast and enhanced absorption of oil-soluble nutrients and therapeutics. The new facility will house several GMP-compliant contract manufacturing suites, equipped with the latest technology to ensure the efficient and precise production of high-quality products.

 

Advanced R&D Laboratory: PBIO is investing in the development of a cutting-edge research and development laboratory, where its team of highly trained and experienced experts will continue to push the boundaries of high-pressure nanotechnology. The laboratory will focus on developing groundbreaking solutions in nanoemulsions and other products for use in nutraceuticals, cosmeceuticals, pharmaceuticals, bioprocess, and other areas.

 

State-of-the-Art Equipment Manufacturing: The facility features a dedicated space for the manufacturing of advanced equipment and components incorporating state-of-the-art materials and designs used in the production of nanoemulsions and other products. This will enable PBIO to expand production capacity in UltraShear equipment installations, while maintaining stringent quality control and ensuring the total reliability of its products.

 

Formulation Services: With a focus on providing comprehensive solutions, PBIO currently offers limited formulation services to its UltraShear clients. With the Canton site’s expanded space and equipment, the Company’s Formulation Services are expected to expand and grow significantly, as it collaborates closely with customers to develop customized formulations tailored to their specific needs and requirements, spanning a diversity of major market applications from nutraceuticals to cosmeceuticals/skincare, pharmaceuticals, food & beverages, and natural, organic agrochemicals.

 

Demo Laboratory: A dedicated Demo Laboratory will showcase the Company’s cutting-edge UltraShear technology platform, allowing stakeholders to witness PBIO’s unique and far-reaching capabilities firsthand.

 

John Hollister, PBIO’s Director of Sales and Marketing, added: “Unlike our previous site, the new facility provides the needed environment for us to accomplish our aggressive commercial goals over the next few years. Our new facility – with its significantly increased manufacturing space – gives us the ability to expand manufacturing capabilities to meet the already increasing demand for our products. Our growth is no longer encumbered by our facilities.”

 

About Uncle Bud’s Health and Wellness

Launched in 2018 with a trailblazing hemp-based Pain Relief product, Uncle Bud’s has rapidly captured an innovative leadership role in the Hemp Seed Oil, Cannabidiol (CBD), and the broader Health & Wellness industry. The Uncle Bud’s brand is revered for its unwavering commitment to domestic manufacturing excellence, setting benchmarks for its organic, preservative-free, non-GMO standards and its ethical cruelty-free practices. Uncle Bud’s is dedicated to the highest-quality formulations and to continuous improvement, guided by the latest scientific research and development innovations – including the revolutionary performance breakthroughs delivered by PBIO’s patented UltraShear™ processing platform. Uncle Bud’s diverse product portfolio addresses an ever-broadening spectrum of consumer needs, encompassing pain relief, sophisticated skincare solutions, personal wellness and athletic recovery products, and specialized pet care items. Learn More: www.unclebudshemp.com * Follow On Social Media: @UncleBuds_Hemp.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Our patented enabling platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. Our patented BaroFold™ technology platform, allowing us to enter the bio-pharma contract services and GMP manufacturing equipment sector. We have also developed the scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Our commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers.

 

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

For more information about PBIO, Uncle Bud’s, and this press release, please click on the following website links:

http://www.pressurebiosciences.com  www.unclebudshemp.com

Please visit us on Facebook, LinkedIn, and Twitter.

 

Press Contacts:

Richard T. Schumacher, President & CEO

(508) 230-1828 (T)

 

John B. Hollister, Director of Sales and Marketing

(805) 908-5719 (T)

 

Kenneth F. Micciche, Director of Business Development

(508) 230-1828 (T)

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure: this news for Pressure BioSciences, Inc. (PBIO) is paid for content on our site. Disclosure More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

 

About Investorideas.com

https://www.investorideas.com/About/

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks